These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1130 related items for PubMed ID: 16783857

  • 1. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N, Kumar S, Stamp L, Gow P.
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [Abstract] [Full Text] [Related]

  • 2. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N, Stamp L.
    Semin Dial; 2007 Aug; 20(5):391-5. PubMed ID: 17897242
    [Abstract] [Full Text] [Related]

  • 3. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
    Arthritis Rheum; 2008 Nov 15; 59(11):1540-8. PubMed ID: 18975369
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.
    J Rheumatol; 2009 Jun 15; 36(6):1273-82. PubMed ID: 19286847
    [Abstract] [Full Text] [Related]

  • 5. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D, Sripradit S, Angthararak S.
    J Clin Rheumatol; 2008 Feb 15; 14(1):6-11. PubMed ID: 18431090
    [Abstract] [Full Text] [Related]

  • 6. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 15; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [Abstract] [Full Text] [Related]

  • 7. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.
    Arthritis Care Res (Hoboken); 2012 Feb 15; 64(2):256-61. PubMed ID: 22052584
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Clin Pharmacol Ther; 2011 Sep 15; 90(3):392-8. PubMed ID: 21796116
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
    Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM.
    Arthritis Rheum; 2002 Dec 15; 47(6):610-3. PubMed ID: 12522834
    [Abstract] [Full Text] [Related]

  • 19. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 15; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.